Safety and efficacy of oral human parathyroid hormone (1-34) in hypoparathyroidism: An open-label study

Sofia Ish-Shalom, Yoseph Caraco, Nariman Saba Khazen, Michal Gershinsky, Auryan Szalat, Phillip Schwartz, Ehud Ehud Arbit, Hillel Galitzer, Jonathan C Y Tang, Gregory Burshtein, Ariel Rothner, Arthur Raskin, Miriam Blum, William Fraser

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)
10 Downloads (Pure)


The standard treatment of primary hypoparathyroidism (hypoPT) with oral calcium supplementation and calcitriol (or an analog), intended to control hypocalcemia and hyperphosphatemia and avoid hypercalciuria, remains challenging for both patients and clinicians. In 2015, human parathyroid hormone (hPTH) (1-84) administered as a daily subcutaneous injection was approved as an adjunctive treatment in patients who cannot be well controlled on the standard treatments alone. This open-label study aimed to assess the safety and efficacy of an oral hPTH(1-34) formulation as an adjunct to standard treatment in adult subjects with hypoparathyroidism. Oral hPTH(1-34) tablets (0.75 mg human hPTH(1-34) acetate) were administered four times daily for 16 consecutive weeks, and changes in calcium supplementation and alfacalcidol use, albumin-adjusted serum calcium (ACa), serum phosphate, urinary calcium excretion, and quality of life throughout the study were monitored. Of the 19 enrolled subjects, 15 completed the trial per protocol. A median 42% reduction from baseline in exogenous calcium dose was recorded (p =.001), whereas median serum ACa levels remained above the lower target ACa levels for hypoPT patients (>7.5 mg/dL) throughout the study. Median serum phosphate levels rapidly decreased (23%, p =.0003) 2 hours after the first dose and were maintained within the normal range for the duration of the study. A notable, but not statistically significant, median decrease (21%, p =.07) in 24-hour urine calcium excretion was observed between the first and last treatment days. Only four possible drug-related, non-serious adverse events were reported over the 16-week study, all by the same patient. A small but statistically significant increase from baseline quality of life (5%, p =.03) was reported by the end of the treatment period. Oral hPTH(1-34) treatment was generally safe and well tolerated and allowed for a reduction in exogenous calcium supplementation, while maintaining normocalcemia in adult patients with hypoparathyroidism.

Original languageEnglish
Pages (from-to)1060-1068
Number of pages9
JournalJournal of Bone and Mineral Research
Issue number6
Early online date5 Mar 2021
Publication statusPublished - Jun 2021

Cite this